Sugi Predict

Sugi Predict / Targets / LIPA

LIPA

Lysosomal acid lipase/cholesteryl ester hydrolase · P38571 · LIPA on Sugi Atlas →

1,400 patent compounds predicted against LIPA, 763 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL17078227 SCHEMBL17078227 1.00 8/20
SCHEMBL17078235 SCHEMBL17078235 1.00 8/20
SCHEMBL17078239 SCHEMBL17078239 1.00 8/20
SCHEMBL17078250 SCHEMBL17078250 1.00 8/20
SCHEMBL17078253 SCHEMBL17078253 1.00 8/20
SCHEMBL17078300 SCHEMBL17078300 1.00 8/20
SCHEMBL19607575 SCHEMBL19607575 1.00 8/20
SCHEMBL19607576 SCHEMBL19607576 1.00 8/20
SCHEMBL19584717 SCHEMBL19584717 0.72 8/20
SCHEMBL22799434 SCHEMBL22799434 0.59 8/20
SCHEMBL11527669 SCHEMBL11527669 0.52 8/20
SCHEMBL4312668 SCHEMBL4312668 0.45 8/20
SCHEMBL11150108 SCHEMBL11150108 0.53 7/20
SCHEMBL2385404 SCHEMBL2385404 0.48 7/20
SCHEMBL11754569 SCHEMBL11754569 0.47 6/20
SCHEMBL17244724 SCHEMBL17244724 0.68 5/20
SCHEMBL9337860 SCHEMBL9337860 0.56 5/20
SCHEMBL11528671 SCHEMBL11528671 0.54 5/20
SCHEMBL1587140 SCHEMBL1587140 0.53 5/20
SCHEMBL1587314 SCHEMBL1587314 0.53 5/20

Clinical trials — most relevant to LIPA by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Effects of Statin and Ezetimibe Association on Kinetics of Artificial Chilomicrons PHASE4COMPLETED
Effect of Evolocumab on Vascular Function PHASE4COMPLETED
Acid Lipase Replacement Investigating Safety and Efficacy (ARISE) in Participants With Lysosomal Acid Lipase Deficiency PHASE3COMPLETED
Safety, Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of Sebelipase Alfa in Children With Growth Failure Due to Lysosomal Acid Lipase Deficiency PHASE2/PHASE3COMPLETED
SOLUTION: Study of Oral Liprotamase Unit-Matched Therapy Of Non-Porcine Origin in Patients With Cystic Fibrosis PHASE3COMPLETED
Safety, Tolerability and Pharmacokinetics of SBC-102 (Sebelipase Alfa) in Adult Participants With Lysosomal Acid Lipase Deficiency PHASE1/PHASE2COMPLETED
Safety and Efficacy Study of Sebelipase Alfa in Participants With Lysosomal Acid Lipase Deficiency PHASE2COMPLETED
Orlistat for the Treatment of Type I Hyperlipoproteinemia PHASE2COMPLETED
CS-121 APOC3 Base Editing in FCS EARLY_PHASE1RECRUITING
An Observational Study of Patients With Lysosomal Acid Lipase Deficiency/Cholesteryl Ester Storage Disease Phenotype nanCOMPLETED
Lysosomal Acid Lipase (LAL) Deficiency Registry nanRECRUITING
Abnormal Lipids - Causes and Effects nanRECRUITING
National Lysosomal Acid Lipase Deficiency Study nanCOMPLETED
Biomarker for Wolman Disease (BioWolman) nanWITHDRAWN
Assessment of the Prevalence of Lysosomal Acid Lipase Deficiency in Patients Waiting for a Liver Transplant. nanUNKNOWN
Assessement of the Prevalence of Lysosomal Acid Lipase Deficiency in Liver Post-transplant Patients nanUNKNOWN
Effect of Saturated Fat on Large Low-density Lipoprotein (LDL) and High-density Lipoprotein (HDL) nanCOMPLETED
Acute Pancreatitis Targets (APT) Study nanCOMPLETED
Study Comparing Blood Levels of Fatty Acids After Consuming Two Forms of Cod Liver Oil nanCOMPLETED
A Retrospective Natural History Study of Patients With Lysosomal Acid Lipase Deficiency/Wolman Phenotype nanCOMPLETED
Study to See How Low Level Laser Light Affects Subcutaneous Fat Around the Hips and Waist nanWITHDRAWN
An Expanded Access Protocol for Sebelipase Alfa for Patients With Lysosomal Acid Lipase Deficiency nanNO_LONGER_AVAILABLE
Lysosomal Acid Lipase Activity in Nonalcoholic Fatty Liver Disease nanCOMPLETED
Plasma Triglyceride Lipolysis in Multifactorial Chylomicronemia nanCOMPLETED
Novel Association of Cholesterol Ester Storage Disease Due to Lysosomal Acid Lipase Deficiency and Non-Alcoholic Fatty Liver Disease: A Prospective Clinical Study nanUNKNOWN
Postprandial Fatty Acid Metabolism in Subjects With Lipoprotein Lipase Deficiency nanRECRUITING
Study to Re-assess and Re-confirm Data Previously Recorded About the Incidence and Severity of Acute Abdominal Pancreatitis Episodes in Lipoprotein Lipase Deficient (LPLD) Subjects Previously Enrolled on AMT Clinical Studies nanUNKNOWN
Effect of Molecular Hydrogen in Patients With NAFLD nanCOMPLETED
Association Between HDL Functions and Atherosclerotic Burden in Healthy Individuals nanCOMPLETED
Triglyceride-rich LIPoproteins and INflammatory Cytokines After Oral FAT Loading as Potential Early Biomarkers of the Risk of Progression Towards DIABETES and Development of Complications. LIPINFAT Diabetes Study. nanRECRUITING

Related proteins — ESM-2 sequence neighbours (a LIPA binder may also engage these)

ProteinNameSimilarity
Q4R4S5 — 1.000 Q4R4S5 →
Q9Z0M5 — 0.986 Q9Z0M5 →
Q8K2A6 — 0.984 Q8K2A6 →
Q5VYY2 — 0.983 Q5VYY2 →
J3SDX8 — 0.979 J3SDX8 →
P80035 — 0.974 P80035 →
Q9CPP7 — 0.973 Q9CPP7 →
Q64194 — 0.972 Q64194 →
P07098 — 0.971 P07098 →
Q29458 — 0.970 Q29458 →
P04634 — 0.963 P04634 →
Q5VXJ0 — 0.962 Q5VXJ0 →
Q8BM14 — 0.953 Q8BM14 →
P52712 — 0.952 P52712 →
Q3U4B4 — 0.942 Q3U4B4 →
Q41005 — 0.939 Q41005 →
P37891 — 0.936 P37891 →
UGT1A1 UDP-glucuronosyltransferase 1A1 0.936 landscape →
UGT1A6 UDP-glucuronosyltransferase 1A6 0.936 landscape →
P11515 — 0.936 P11515 →
Q64550 — 0.935 Q64550 →
Q6ZQM8 — 0.935 Q6ZQM8 →
UGT1A3 UDP-glucuronosyltransferase 1A3 0.934 landscape →
UGT1A4 UDP-glucuronosyltransferase 1A4 0.934 landscape →
P32826 — 0.934 P32826 →
P08430 — 0.934 P08430 →
Q64435 — 0.933 Q64435 →
Q63886 — 0.933 Q63886 →
B4F753 — 0.932 B4F753 →
Q62452 — 0.932 Q62452 →